1.
Br J Dermatol
; 187(2): 275-276, 2022 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35266142
2.
Br J Dermatol
; 187(1): 126-127, 2022 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35048357
RESUMO
Enfortumab vedotin (EV), a novel antibody-drug conjugate approved for metastatic urothelial carcinoma, causes a variety of cutaneous adverse reactions. We present two cases of bullous eruptions following treatment with EV, both demonstrating IgG deposition on direct immunofluorescence (DIF) correlating to the location of nectin-4 in the epidermis. This suggests that the IgG component of EV binding to nectin-4 in keratinocytes is likely a primary contributor to the high rates of cutaneous toxicity.